Behavioral interventions may prolong remission in patients with inflammatory bowel disease

Behaviour Research and Therapy

Volumn 49, Issue 3, 2011, Pages 145-150

  Keefer, Laurie ^a   Kiebles, Jennifer L ^a   Martinovich, Zoran ^a   Cohen, Elyse ^a   Van Denburg, Alyssa ^a   Barrett, Terrence A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Behavioral self management; Crohn's disease; Hypnotherapy; IBD; Remission; Ulcerative colitis

Indexed keywords

ADULT; AGED; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENTERITIS; FEMALE; HUMAN; HYPNOSIS; MALE; REMISSION; SELF CARE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; COGNITIVE THERAPY; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPNOSIS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RECURRENCE; REGRESSION ANALYSIS; SELF CARE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79951676944     PISSN: 00057967     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brat.2010.12.005     Document Type: Article

References (43)

1. Ananthakrishnan A.N., Weber L.R., Knox J.F., Skaros S., Emmons J., Lundeen S., et al. Permanent work disability in Crohn's disease. American Journal of Gastroenterology 2008, 103(1):154-161. doi: AJG1561 [pii]10.1111/j.1572-0241.2007.01561.x.
2. Bernstein C.N. Treatment of the extraintestinal manifestations of inflammatory bowel disease. Current Gastroenterology Report 2002, 4(6):513-516.
3. Bernstein C.N., Fried M., Krabshuis J.H., Cohen H., Eliakim R., Fedail S., et al. World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010. Inflammatory Bowel Disease 2010, 16(1):112-124. 10.1002/ibd.21048.
4. Bernstein C.N., Singh S., Graff L.A., Walker J.R., Miller N., Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. American Journal of Gastroenterology 2010, doi: ajg2010140 [pii]10.1038/ajg.2010.140.
5. Best W.R., Becktel J.M., Singelton J.W., Kern F. Development of a Crohn's disease activity index: national cooperative crohn's disease study. Gastroenterology 1976, 70(3):439-444.
6. Bitton A., Sewitch M., Peppercorn M.A., deB Edwardes M.D., Shah S., Ransil B., et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. The American Journal of Gastroenterology 2003, 98(10):2203-2208.
7. D'Haens G., Sandborn W.J., Feagan B.G., Geboes K., Hanauer S.B., Irvine E.J., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132(2):763-786. doi: S0016-5085(06)02688-6 [pii]10.1053/j.gastro.2006.12.038.
8. D'Haens G.R., Fedorak R., Lemann M., Feagan B.G., Kamm M.A., Cosnes J., et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflammatory Bowel Disease 2009, 15(10):1599-1604. 10.1002/ibd.21034.
9. Elson C. Genes, microbes, and T cells-new therapeutic targets in Crohn's disease. New England Journal of Medicine 2002, 346:614-616.
10. Farhadi A., Keshavarzian A., Van De Kar L.D., Jakate S., Domm A., Zhang L., et al. Heightened response to stressors in patients with inflammatory bowel disease. Gastroenterology 2005, 100:1796-1804.
11. Feagan B.G., Bala M., Yan S., Olson A., Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn's disease. Journal of Clinical Gastroenterology 2005, 39(5):390-395. doi: 00004836-200505000-00010 [pii].
12. Gibson T.B., Ng E., Ozminkowski R.J., Wang S., Burton W.N., Goetzel R.Z., et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. Journal of Occupational and Environmental Medicine 2008, 50(11):1261-1272. doi: 10.1097/JOM.0b013e318181b8ca00043764-200811000-00007 [pii].
13. Hanauer S. Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nature Clinical Practice Gastroenterology and Hepatology 2004, 1(1):26-31.
14. Higgins P.D., Rubin D.T., Kaulback K., Schoenfield P.S., Kane S.V. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Alimentary Pharmacology & Therapeutics 2009, 29(3):247-257. doi: APT3865 [pii]10.1111/j.1365-2036.2008.03865.x.
15. Katz J.A. Management of inflammatory bowel disease in adults. Journal of Digestive Diseases 2007, 8(2):65-71. doi: CDD287 [pii]10.1111/j.1443-9573.2007.00287.x.
16. Keefer L., Keshavarzian A. Feasibility and acceptability of gut-directed hypnosis on inflammatory bowel disease: a brief communication. International Journal of Clinical and Experimental Hypnosis 2007, 55(4):457-466. doi: 781773163 [pii]10.1080/00207140701506565.
17. Keefer, L., Kiebles, J., Kwiatek, M., Palsson, O., Taft, T. H., Martinovich, Z.et al. The effect of gut-directed hypnotherapy on ulcerative colitis: preliminary results from the ulcerative colitis relapse prevention trial (UCRPT). Biological Research for Nursing, in press.
18. Keefer L., Kiebles J.L., Barrett T.A. The role of gut-directed hypnotherapy on relapse prevention in Ulcerative Colitis 2008, Northwestern University: NIH-NCCAM.
19. Keller W., Pritsch M., vonWietersheim J., Scheib P., Osborn W., Balck F., et al. Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohn's disease: main results of the Gernam Prospective Multicenter Psychotherapy Treatment study on Crohn's Disease. Journal of Psychosomatic Research 2004, 56(6):687-696.
20. Kennedy A.P., Nelson E., Reeves D., Richardson G., Roberts C., Robinson A., et al. A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut 2004, 53(11):1639-1645. doi: 53/11/1639 [pii]10.1136/gut.2003.034256.
21. Kiebles J.L., Doerfler B., Keefer L. Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease. Inflammatory Bowel Disease 2010, 10.1002/ibd.21215.
22. Kiliaan A., Saunders P.R., Bijlsma P.B., Berin M.C., Taminiau J.A., Groot J.A., et al. Stress stimulates transepithelial macromolecular uptake in rat jejuenum. American Journal of Physiology: Gastrointestinal Liver Physiology 1998, 275:G1037-G1044.
23. Levenstein S. Psychosocial factors in peptic ulcer and inflammatory bowel disease. Journal of Consulting and Clinical Psychology 2002, 70:739-750.
24. Levenstein S., Prantera C., Varvo V., Scriabno M.L., Andreoli A., Luzi C., et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. American Journal of Gastroenterology 2000, 95(5):1213-1219.
25. Lewis M. Attributions and inflammatory bowel disease: patients' perceptions of their ilness causes and effects of these perceptions on relationships. AARN News Letter 1998, 16.
26. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influences. Gastroenterology 2004, 126(6):1504-1517.
27. Longobardi T., Bernstein C.N. Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. American Journal of Gastroenterology 2007, 102(8):1683-1691. doi: AJG1232 [pii]10.1111/j.1572-0241.2007.01232.x.
28. Marri S., Buchman A.L. The education and employment status of patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2005, 11(2):171-177.
29. Mawdsley J.E., Macey M.G., Feakins R.M., Langmead L., Rampton D.S. The effect of acute psychological stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology 2006, 131:410-419.
30. Mesalamine Study Group An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomised, placebo controlled trial. Annals of Internal Medicine 1996, 124:204-221.
31. Milde A., Enger O., Murison R. The effects of postnatal maternal separation on stress responsivity and experimentally induced colitis in adult rats. Physiology and Behavior 2004, 81:71-84.
32. Million M., Tache Y., Anton P. Susceptibility of Lewis and Fisher rats to stress-induced worsening of TNB colitis: protective role of brain CRF. American Journal of Physiology 1999, 276:G1027-G1036.
33. Moser G., Maeir-Dobersberger T., Vogelsang H., Lochs H. Inflammatory bowel disease: patients beliefs about the etiology of their disease - a controlled study. Psychosomatic Medicine 1993, 55:131.
34. Rogala L., Miller N., Graff L.A., Rawsthorne P., Clara I., Walker J.R., et al. Population-based controlled study of social support, self-perceived stress, activity and work issues, and access to health care in inflammatory bowel disease. Inflammatory Bowel Disease 2008, 14(4):526-535. 10.1002/ibd.20353.
35. Sandborn W.J. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Reviews in Gastroenterological Disorders 2006, 6(2):97-105.
36. Sandborn W.J., Feagan B.G., Lichtenstein G.R. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Alimentary Pharmacology Therapeutics 2007, 26(7):987-1003. doi: APT3455 [pii]10.1111/j.1365-2036.2007.03455.x.
37. Schroeder K., Tremaine W., Ilstrup D. Coated oral 5-aminosalcylic acid therapy for mildly to moderately active ulcerative colitis. New England Journal of Medicine 1987, 317:1625-1629.
38. Schwarz S.P., Blanchard E.B. Evaluation of a psychological treatment for inflammatory bowel disease. Behaviour Research and Therapy 1991, 29(2):167-177.
39. Shanahan F., Bernstein C.N. The evolving epidemiology of inflammatory bowel disease. Current Opinion in Gastroenterology 2009, 25(4):301-305. 10.1097/MOG.0b013e32832b12ef.
40. Singh S., Graff L.A., Bernstein C.N. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD?. American Journal of Gastroenterology 2009, 104(5):1298-1313. quiz 1314. doi: ajg200915 [pii]10.1038/ajg.2009.15.
41. Tache Y., Martinez V., Wang L., Million M. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. British Journal of Pharmacology 2004, 141(8):1321-1330.
42. Thia K.T., Sandborn W.J., Lewis J.D., Loftus E.V., Feagan B.G., Steinhart A.H., et al. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol 2008, 103(12):3123-3131. doi: AJG2176 [pii]10.1111/j.1572-0241.2008.02176.x.
43. Walker J.R., Ediger J.P., Graff L.A., Greenfeld J.M., Clara I., Lix L., et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. American Journal of Gastroenterology 2008, 103(8):1989-1997. doi: AJG1980 [pii]10.1111/j.1572-0241.2008.01980.x.